- The key vendors in the Global Osteoarthritis Market 2015-2019 are Abbott Laboratories Ltd., Johnson & Johnson Ltd., Novartis AG and Pfizer Inc.
London, 11 March 2015: TechNavio, an independent tech-focused global research firm, has announced the publication of its market research report on the Global Osteoarthritis Market 2015-2019. The presence of various large and small pharmaceutical companies increases the competition in the market. Various vendors are extensively forming strategic alliances to increase their market share. For instance, in 2013, Merck Serono and Biopharm collaborated to research the molecular engineering of a biologic compound for the treatment of osteoarthritis. The Global Osteoarthritis market is expected to grow at a CAGR of 8.55 percent during the forecast period of 2014-2019.
“Various companies are conducting clinical trials of a new class of pain medications called anti-NGFs. These are biologic drugs that block NGF, a protein associated with pain,” says Faisal Ghaus, Vice President of TechNavio Research.
“Moreover, the efficacy of selective PDE2 inhibitors is being evaluated in rat models to be used for relieving pain caused by osteoarthritis in humans.”
To define the market conditions in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
